News releases Year None202220212019 Nov 01, 2022 Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update PDF Version Sep 30, 2022 Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version Aug 15, 2022 Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update PDF Version Jul 12, 2022 Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version Jun 28, 2022 Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference PDF Version May 19, 2022 Pyxis Oncology Announces Presentations at Upcoming Investor Conferences PDF Version May 13, 2022 Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update PDF Version Apr 27, 2022 Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference PDF Version Apr 13, 2022 Pyxis Oncology Announces Leadership Changes PDF Version Apr 08, 2022 Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting PDF Version Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
Year None202220212019 Nov 01, 2022 Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update PDF Version Sep 30, 2022 Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version Aug 15, 2022 Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update PDF Version Jul 12, 2022 Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version Jun 28, 2022 Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference PDF Version May 19, 2022 Pyxis Oncology Announces Presentations at Upcoming Investor Conferences PDF Version May 13, 2022 Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update PDF Version Apr 27, 2022 Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference PDF Version Apr 13, 2022 Pyxis Oncology Announces Leadership Changes PDF Version Apr 08, 2022 Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting PDF Version Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
